Research map: Treatment patterns and outcomes of second/third-line therapy in advanced non-small cell lung cancer with actionable genomic alterations (RECAP)

Back to the article

Papers in this map

  1. Global cancer statistics 2022: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries · Freddie Bray · 2024 · 26051 citations · Cited by this paper
  2. Impact of neoadjuvant cetuximab on liver function and tumor reduction in a murine model of selective portal vein ligation · 2025 · Related
  3. Rebiopsy of Lung Cancer Patients with Acquired Resistance to EGFR Inhibitors and Enhanced Detection of the T790M Mutation Using a Locked Nucleic Acid-Based Assay · Maria E. Arcila · 2011 · 580 citations · Cited by this paper
  4. The challenge of disappearing colorectal liver metastasis: balancing considerations between tumor biology and clinical consequence for liver surgery · 2025 · Related
  5. RET Fusions Define a Unique Molecular and Clinicopathologic Subtype of Non–Small-Cell Lung Cancer · Rui Wang · 2012 · 557 citations · Cited by this paper
  6. Gamma knife radiosurgery for cerebellar brain metastases: clinical outcomes and artificial intelligence-based predictive modeling · 2026 · Related
  7. [Cancer incidence and mortality in China, 2022]. · Rongshou Zheng · 2024 · 466 citations · Cited by this paper
  8. Importance of the timing of combined electrochemotherapy and immunotherapy in the treatment of advanced melanoma · 2025 · Related
  9. The Evolving Role of Histology in the Management of Advanced Non–Small-Cell Lung Cancer · Corey Jay Langer · 2010 · 304 citations · Cited by this paper
  10. FOXM1 expression is induced by the brain microenvironment and supports CRC brain metastatic adaptation · 2026 · Related
  11. Genomic Signature of Driver Genes Identified by Target Next-Generation Sequencing in Chinese Non-Small Cell Lung Cancer · Shiwang Wen · 2019 · 130 citations · Cited by this paper
  12. CYP4B1 inhibits lung adenocarcinoma metastasis by downregulating slug transcription via Sp1 · 2026 · Related
  13. Genomic Alterations and the Incidence of Brain Metastases in Advanced and Metastatic NSCLC: A Systematic Review and Meta-Analysis · Conor Scott Gillespie · 2023 · 117 citations · Cited by this paper
  14. Prognostic influence of chronic inflammation in patients with head and neck cancer based on sex differences · 2025 · Related
  15. Acquired resistance to targeted therapies in NSCLC: Updates and evolving insights · Catherine Belle Meador · 2020 · 114 citations · Cited by this paper
  16. Contribution of tumor-derived extracellular vesicles in the establishment of the pre-metastatic niche: lessons learned from past experimentations and future directions · 2026 · Related
  17. The association between BRAF mutation class and clinical features in BRAF-mutant Chinese non-small cell lung cancer patients · Quan D. Lin · 2019 · 71 citations · Cited by this paper
  18. Targeting metabolic and epigenetic reprogramming in metastatic fumarate hydratase-deficient renal cell carcinoma · 2025 · Related
  19. Prevalence of ROS1 fusion in Chinese patients with non‐small cell lung cancer · Qing Zhang · 2018 · 50 citations · Cited by this paper
  20. Encapsulated histopathological growth pattern of colorectal liver metastases predicts prolonged survival after repeat liver resection for recurrence · 2026 · Related
  21. Comparative effectiveness of pembrolizumab vs. nivolumab in patients with recurrent or advanced NSCLC · Pengfei Cui · 2020 · 50 citations · Cited by this paper
  22. Impact of Broadening Trial Eligibility Criteria for Patients with Advanced Non–Small Cell Lung Cancer: Real-World Analysis of Select ASCO- Friends Recommendations · Robert Donald Harvey · 2021 · 48 citations · Cited by this paper
  23. Continuing EGFR-TKI beyond radiological progression in patients with advanced or recurrent, EGFR mutation-positive non-small-cell lung cancer: an observational study · Yasushi Goto · 2017 · 42 citations · Cited by this paper
  24. The Importance of Patient Reported Outcomes in Oncology Clinical Trials and Clinical Practice to Inform Regulatory and Healthcare Decision-Making · Stefania Bellino · 2024 · 39 citations · Cited by this paper
  25. Real‐world EGFR testing in patients with stage IIIB/IV non‐small‐cell lung cancer in North China: A multicenter, non‐interventional study · Ying Cheng · 2018 · 37 citations · Cited by this paper
  26. Oligoprogression in non-small cell lung cancer: a narrative review · Katarina T. Nguyen · 2022 · 36 citations · Cited by this paper
  27. Real-World Data of Different Immune Checkpoint Inhibitors for Non-Small Cell Lung Cancer in China · Kang Miao · 2022 · 32 citations · Cited by this paper
  28. COMPEL: osimertinib plus platinum-based chemotherapy in patients with EGFR-mutated advanced NSCLC and progression on first-line osimertinib · Nir Peled · 2025 · 32 citations · Cited by this paper
  29. Immunotherapy as second‐line treatment and beyond for non‐small cell lung cancer in a single center of China: Outcomes, toxicities, and clinical predictive factors from a real‐world retrospective analysis · Minjiang Chen · 2020 · 31 citations · Cited by this paper
  30. Real-World Efficacy and Safety of Anlotinib With and Without Immunotherapy in Advanced Non-Small Cell Lung Cancer · Qi Xiong · 2021 · 31 citations · Cited by this paper
  31. Real-world outcomes of chemo-antiangiogenesis versus chemo-immunotherapy combinations in EGFR-mutant advanced non-small cell lung cancer patients after failure of EGFR-TKI therapy · Xin Yu · 2021 · 31 citations · Cited by this paper
  32. Heterogeneity and Coexistence of T790M and T790 Wild-Type Resistant Subclones Drive Mixed Response to Third-Generation Epidermal Growth Factor Receptor Inhibitors in Lung Cancer · Zofia Piotrowska · 2018 · 29 citations · Cited by this paper
  33. Oligoprogression in Non-Small Cell Lung Cancer · Daijiro Harada · 2021 · 27 citations · Cited by this paper
  34. Genomic and clinical characteristics of MET exon14 alterations in a large cohort of Chinese cancer patients revealed distinct features and a novel resistance mechanism for crizotinib · Tianli Cheng · 2020 · 20 citations · Cited by this paper
  35. Real-world treatment efficacy of anti-programmed death-1 combined with anti-angiogenesis therapy in non-small cell lung cancer patients · Lupeng Qiu · 2020 · 18 citations · Cited by this paper
  36. Comparison of Chemotherapy Plus Pembrolizumab vs. Chemotherapy Alone in EGFR-Mutant Non–small-Cell Lung Cancer Patients · Minjiang Chen · 2022 · 17 citations · Cited by this paper
  37. Osimertinib alone as second-line treatment for brain metastases (BM) control may be more limited than for non-BM in advanced NSCLC patients with an acquired EGFR T790M mutation · Changhui Li · 2021 · 13 citations · Cited by this paper
  38. Trends in Molecular Testing of Lung Cancer in Mainland People’s Republic of China Over the Decade 2010 to 2019 · Wenbin Li · 2021 · 12 citations · Cited by this paper
  39. Treatment strategy, overall survival and associated risk factors among patients with unresectable stage IIIB/IV non-small cell lung cancer in China (2015–2017): A multicentre prospective study · Yuankai Shi · 2022 · 12 citations · Cited by this paper

Source: OpenAlex (CC0)